Abstract

GE HEALTHCARE TECHNOLOGIES INC is scheduled to report on April 29, 2026 Pre-Market; this preview outlines consensus expectations for revenue, profitability, and adjusted EPS, reviews last quarter’s delivery versus expectations, and synthesizes current-quarter drivers from product clearances, order momentum, and operating execution.

Market Forecast

Consensus for the first quarter of 2026 points to revenue of 5.04 billion US dollars, up 8.01% year over year, EBIT of 720.55 million US dollars, up 7.64% year over year, and adjusted EPS of 1.05, up 14.95% year over year. There is no explicit market forecast for gross margin or net margin in the current dataset.

The commercial mix remains led by large equipment and solutions with an expanding software and diagnostics footprint; multiple regulatory clearances for new imaging hardware and radiology software this quarter support a constructive order-to-revenue conversion outlook. The most promising near-term contributor is Imaging, with revenue of 9.25 billion US dollars in the latest breakdown; we model year-over-year growth broadly in line with the consolidated estimate of 8.01% for this quarter given the cadence of platform launches and approvals.

Last Quarter Review

In the most recently reported quarter, GE HEALTHCARE TECHNOLOGIES INC delivered revenue of 5.70 billion US dollars (+7.13% year over year), a gross profit margin of 39.68%, GAAP net profit attributable to shareholders of 589.00 million US dollars (net margin 10.34%), and adjusted EPS of 1.44 (-0.69% year over year). Sequentially, net profit improved by 32.06%.

One financial highlight was execution versus expectations: revenue exceeded the consensus by 86.96 million US dollars, EBIT of 950.00 million US dollars was 19.55 million US dollars above the estimate, and adjusted EPS beat by 0.04. On the business side, Imaging remained the largest revenue contributor at 9.25 billion US dollars in the latest breakdown, followed by Advanced Visualization Solutions at 5.35 billion US dollars, Patient Care Solutions at 3.09 billion US dollars, and Pharmaceutical Diagnostics at 2.90 billion US dollars, with “Other” at 40.00 million US dollars; the combination of new platform approvals and continued installed-base activity supported top-line momentum.

Current Quarter Outlook

Main business trajectory and profitability setup

The company enters the first quarter of 2026 with consensus looking for revenue of 5.04 billion US dollars (+8.01% year over year) and EPS of 1.05 (+14.95% year over year), implying incremental margin capture as operating expense growth trails revenue. The expected 7.64% year-over-year increase in EBIT (to 720.55 million US dollars) is directionally consistent with a stable-to-improving gross-profit conversion, and with last quarter’s 39.68% gross margin as a baseline, investors will watch whether pricing, mix, and productivity keep unit economics resilient. Mix is an important swing factor: contributions from higher-value modalities and software can support margins, while a larger share of new equipment shipments versus services can temporarily dilute margins before service annuities ramp.

Operationally, order intake and conversion timing will influence whether revenue skews toward equipment or services in the quarter. Recent clearances for new MRI and CT systems and radiology software suite upgrades enhance the catalog available for near-term bookings, though revenue recognition depends on shipment and installation schedules. Cost discipline remains visible through the lens of EBIT growth tracking revenue; modest overhead leverage combined with procurement and supply-chain normalization can help preserve gross-profit margin even if component and logistics costs fluctuate.

Foreign exchange and geographic revenue mix may add noise but are typically manageable within guidance bands. With last quarter revenue outpacing expectations by 86.96 million US dollars and EBIT ahead by 19.55 million US dollars, the current setup suggests the bar is balanced: a modest beat requires continued execution in order conversion and expense control, while any delivery friction could limit upside given the tougher year-ago comparables embedded in the 14.95% EPS growth expectation.

Most promising business and growth catalysts

Imaging stands out as the most promising near-term growth contributor, reflecting both new product availability and a healthy modernization cycle. In the latest business mix, Imaging revenue is 9.25 billion US dollars, providing a substantial base from which even mid-single- to high-single-digit growth can translate into meaningful absolute dollar gains. Regulatory progress this quarter—new CT photon-counting platforms, 1.5T and 3T MRI system clearances, and workflow-centric radiology software—enhances clinical value propositions and can accelerate order pipelines in regions with robust capital budgets.

Beyond new system wins, the Imaging installed base drives recurring upgrades, applications, and service activity, which stabilizes revenue and margin through the cycle. The addition of browser-based, AI-enabled image review and advanced visualization as part of an integrated workspace can increase software attachment rates and expand the revenue-per-system opportunity. As these platforms scale, Imaging growth can track or exceed the consolidated revenue growth forecast of 8.01% year over year for this quarter, especially if recently cleared systems begin shipping and acceptance milestones are met before quarter end.

Pharmaceutical Diagnostics also offers a supportive tailwind as procedure volumes normalize and contrast agent demand tracks imaging throughput. While its revenue in the latest mix is 2.90 billion US dollars—smaller than Imaging—it benefits from volume elasticity tied to patient throughput. Together, these dynamics position the portfolio to convert innovation and utilization into a favorable revenue and cash profile, assuming supply continuity for key components and continued procedural resilience.

Stock-price drivers this quarter

Relative to consensus, three swing factors are likely to drive the stock reaction. First, the spread between revenue growth (+8.01% year over year expected) and EPS growth (+14.95% year over year expected) embeds operating leverage; clear evidence of gross-margin resilience and overhead control will determine whether that spread is realized. Any commentary on pricing discipline, productivity initiatives, and product cost curves will be scrutinized as read-throughs for the remainder of 2026. Second, the cadence of product launches and regulatory wins versus revenue recognition will dictate near-term sales composition; a higher ratio of equipment shipments can support revenue momentum but may temporarily weigh on mix until services and upgrades ramp.

Third, updates to full-year guardrails and bookings visibility may influence valuation more than the quarter itself. The company’s previously communicated full-year adjusted EPS framework of 4.95 to 5.15 signals confidence in underlying demand and self-help; reiteration at the quarter along with any color on order growth, book-to-bill, or conversion timelines can recalibrate expectations. Post-print, investors will also watch cash metrics—working capital tied to inventory for new systems and collections on recent shipments—as well as any incremental capital allocation commentary.

Operational themes to monitor

- New platform adoption: The quarter brings multiple cleared systems and software. Concrete disclosures on order intake for these offerings and early customer deployments can validate the growth thesis and inform revenue phasing into the second half. - Services and software expansion: Evidence of attachment-rate improvement and cross-selling into the installed base would underpin the EPS growth gap versus revenue by contributing higher-margin revenue streams. - Supply chain and manufacturing throughput: Lead times and component availability remain operational priorities. Demonstrated improvement or stability here supports shipment reliability and working-capital efficiency. - Regional sales balance: While detailed regional data are not in the current dataset, management commentary on demand dynamics by geography will help contextualize the consolidated revenue forecast and set expectations for the next quarter.

Analyst Opinions

Bullish views dominate in the current window, anchored by institutional consensus that sits above the midpoint of the company’s full-year framework and aligns with double-digit adjusted EPS growth for the first quarter. FactSet-based sell-side consensus implies revenue of 5.04 billion US dollars (+8.01% year over year) and adjusted EPS of 1.05 (+14.95% year over year), a profile consistent with a constructive stance toward margin stability and execution on recently launched platforms. The market’s reaction to regulatory milestones—such as the clearance of the Photonova Spectra CT system and new MRI platforms—paired with guidance that frames full-year adjusted EPS at 4.95 to 5.15, has reinforced the view that earnings quality can improve as the year progresses.

The bullish argument emphasizes three threads. First, consensus embeds prudent but rising profitability—EBIT projected at 720.55 million US dollars (+7.64% year over year)—which suggests that cost and mix controls are gaining traction following the prior quarter’s delivery that exceeded revenue and EBIT expectations. Second, product-cycle momentum in Imaging and software-enabled workflows provides visible levers for order growth and conversion, supporting both top-line expansion and higher-margin recurring revenue as upgrades and service agreements attach. Third, the full-year EPS framework serves as a stabilizing anchor; reiteration alongside first-quarter delivery would bolster confidence in run-rate earnings even if macro or procurement timing introduces short-term variability.

From a positioning standpoint into the print, bullish previews point to a balanced setup with potential upside if revenue conversion from newly cleared platforms surprises to the high end and if gross margin remains near last quarter’s 39.68% despite mix shifts. Commentary on bookings and the pace of shipments for the MRI and CT launches, as well as early uptake of the radiology software suite, will be key confirmation points. Provided these elements align with consensus, the growth and margin profile implied by the first-quarter forecast appears achievable, leaving room for positive revisions should order strength translate into stronger second-quarter visibility.